INI Welcomes Dr. Samudrala
Dr. Samudrala has joined INI beginning Aug 1.
ASCO: No Benefit from Avastin in Glioblastoma. Patients with newly diagnosed glioblastoma lived no longer with the addition of bevacizumab (Avastin) to chemoradiation than they did without it, results of a large multicenter trial showed.
SOURCE: Gilbert MR, et al “RTOG 0825: Phase III double-blind, placebo-controlled trial evaluating bevacizumab in patients with newly diagnosed glioblastoma” ASCO 2013; Abstract 1.